Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.

Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Philip Friedlander, Andrew S. Brohl, Adil Daud, Harriet M. Kluger, Sunil Reddy,

Journal of Clinical Oncology · 2018 · 23 citations · 0 references

Concepts

Abstract

9506 Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus (MCPyV). Clinical trials of PD-1-axis blocking agents in aMCC have demonstrated increased progression free survival (PFS) compared to historical data from patients (pts) receiving chemotherapy, but data on response durability and OS are limited. Here we report outcomes from the expanded phase 2 Cancer Immunotherapy Trials Network-09 trial of pembrolizumab (PEM, anti-PD-1) in the first-line setting (NCT02267603). Methods: Adults with aMCC, naïve to systemic therapy for aMCC, received PEM (2 mg/kg Q3W) for up to 2 yrs. Responses per RECIST v1.1 were assessed centrally based on CT scans performed at 12 wks and Q9W thereafter. Tumor MCPyV status was assessed by serum antibody titer and/or IHC for MCPyV oncoprotein. Preliminary results from the first 26 pts have been reported (Nghiem NEJM 2016). We now include data from an expansion cohort of 24 pts. Results: 50 pts (43 stage IV, 7 unresectable stage IIIB) were enrolled 01/2015 – 05/2017. 80% of pts were ≥65 yrs of age. As of 06/21/17, median follow-up was 8.6 mo (range 0.4 - 29 mo). Among tumors from 49 pts, 65% were MCPyV+. Of 42 pts with ≥21 wk follow-up, confirmed ORR was 50% (95% CI 34.2-65.8; CR 19%, PR 31%). ORR was 52% and 44% in pts with MCPyV (+) and (-) tumors, respectively. Median PFS was not reached (NR; 95% CI 2.9 mo - Not Estimable). OS rate at 18 mo was 68% and median OS was NR, comparing favorably to historical first-line chemotherapy data (18 mo OS rate ~30%; Iyer 2016 & Cowey 2017). Among 21 confirmed responders, median response duration was NR (range 3.9+ to 25.6+ mo). Treatment-related adverse events (TRAE) of any grade (CTCAE v4.0) were seen in 47/50 pts (94%); 15 pts (30%) experienced a grade ≥3 TRAE, including 1 treatment-related death. TRAEs led to discontinuing PEM in 6 pts (12%). Conclusions: These results represent the longest observation to date of patients with aMCC receiving first-line anti-PD-1, and demonstrate durable tumor control, a favorable OS rate, and a manageable safety profile. An additional 7.5 mos of follow-up and correlative studies including tumor PD-L1 expression will be presented. Clinical trial information: NCT02267603.